Navigation Links
New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
Date:8/27/2007

MELBOURNE, Australia, Aug. 28 /PRNewswire/ -- Cancer Therapeutics CRC Pty Ltd (CTx) has commenced operations as one of the largest public/private partnerships of its type in the world.

Underpinned by AUD$148 million in funding over seven years, including AUD$37.6 million from the Australian Commonwealth Government, CTx addresses the gap between Australia's excellent academic cancer research base and its ability to discovery and develop new drugs to treat cancer.

The company is now seeking projects -- "big ideas about small molecules" -- from research organisations in Australia. One of the first projects is to discover and develop compounds directed at BNO69, the CTx participant Adelaide-based Bionomics Limited's own proprietary cancer target.

The CTx will create a dedicated drug discovery capability and drive the discovery, development and commercialisation of new compounds against in-licenced novel molecular targets from research organisations and small biotechnology companies across Australia, and in some cases overseas. Ultimately this will lead to the development of more effective cancer drugs. The innovative approach of CTx, funded under the Commonwealth Government's Cooperative Research Centre (CRC) scheme, will transform the discovery and early development of new therapies that might otherwise languish from a lack of supporting funds, resources and expertise.

Dr Julian Clark, Melbourne-based CEO of CTx, says: "While organisations such as Australia's National Health and Medical Research Council (NHMRC) and the Australian Research Council (ARC) provide excellent support for researchers and organisations pursuing basic scientific investigation, continuing financial support for further development of potential commercial targets has proven problematic. This is largely due to the inherent increased risks and the accelerating costs in any attempts to translate promising compounds into prospective drugs and the lack of funds for early
'/>"/>

SOURCE Cancer Therapeutics CRC Pty Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
4. FDA Announces Results of Investigation Into Illegal Promotion of OxyContin by The Purdue Frederick Company, Inc.
5. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
6. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
7. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
8. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
11. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...ptimizing Patient Identification for Targeted Ther...lized Treatment HUNTINGTON BEACH, Calif., and A...ndia, a world leader in molecular cancer diagnosti...a new diagnostic test that,allows physicians to qu...of,the estrogen receptor (ER), progesterone recept...
(Date:9/3/2008)...n College of Rheumatology Research and Education F...ificant Advances in Detecting, .../- For the first time during its,unpr... arthritis, the,American College of Rheumatology R...information acquired from research funded by the W...
(Date:9/3/2008)...is showed that Multaq(R) (dronedarone) decreased t...brillation or atrial flutter already ...DGEWATER, N.J., Sept. 3 /- ...m the ATHENA study were presented today at,the cli... of Cardiology,congress 2008, in Munich, Germany. ...
(Date:9/3/2008)...ermany, Sept. 3 /- A sub-an... that treatment with prasugrel,compared with clopi...current heart attacks (7.4 percent vs. 9.7 percent...rred around the time of an artery-opening,procedur...), or if they,occurred spontaneously during the lo...
Breaking Medicine Technology:Agendia Launches TargetPrint(R) for Breast Cancer Patients 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6The impact of physical activity on weight bearing knee joint 2297 1The impact of physical activity on weight bearing knee joint 2297 2The impact of physical activity on weight bearing knee joint 2297 3Dysfunctional families and bad neighborhoods may worsen asthma in children and adolescents 2294 1Dysfunctional families and bad neighborhoods may worsen asthma in children and adolescents 2294 2Dysfunctional families and bad neighborhoods may worsen asthma in children and adolescents 2294 3APHA Urges President Bush Not To Veto CHIP 3B Were Only One Signature Away from Protecting the Health of Our Children 2291 1APHA Urges President Bush Not To Veto CHIP 3B Were Only One Signature Away from Protecting the Health of Our Children 2291 2Stater Bros Introduces New Healthy Selections Dietitian Program 2288 1Stater Bros Introduces New Healthy Selections Dietitian Program 2288 2
...WIRE)--Jun 25, 2007 - Elixir,Pharmaceuticals, Inc.... highlighting the ability of Glufast(R) (mitiglini...erapy with metformin, to,manage glucose surges bef...e Abstract Book for the American Diabetes,Associat...linois.,Glufast is an insulin secretagogue that lo...
...WIRE)--Jun 25, 2007 - Columbia,Laboratories, Inc. ...lysis of a pregnancy study comparing the efficacy ...intramuscular progesterone,(IMP) injections is now...ty and Sterility, the journal of the American Soci...g prospective randomized controlled study is,evalu...
Other Medicine Technology:Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5Interim Analysis of Crinone Pregnancy Study to Be Published in,American Society for Reproductive Medicine Journal 2Interim Analysis of Crinone Pregnancy Study to Be Published in,American Society for Reproductive Medicine Journal 3Interim Analysis of Crinone Pregnancy Study to Be Published in,American Society for Reproductive Medicine Journal 4
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...ocon Ltd. Thursday announced a 15 percent surge in... Rs.9.9 billion in fiscal 2006-07. // The firm's...006-07, also increased by 86 percent at Rs.380 mil...announced increase in dividend from 50 to 60 perce...
...beneficial aspects of the green tea, saying that i.../ Scientists have earlier shown that antioxidant p...herosclerosis, particularly coronary artery diseas...archers led by Stephen Hsu, from the Medical Colle...
...nter in Bethesda in Maryland, USA, has launched a ... // It is now calling upon all mothers who deliver...series of Shaken Baby Syndrome educational briefin...uld result in permanent danger or even death to in...
... Beijing Olympics, and to provide the best for the...e good air//, and thus remain healthy. The U.S. De...as been exploring this option with leading institu...n Agency, the University of Tennessee, Tsinghua Un...
Other Medicine News:Health News:Counseling to Mothers Against too Much Shaking of Children 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device.
Clinicians are demanding smaller, higher performing systems specifically designed to meet their clinical and operational challenges. The new Philips HD11 XE system provides a powerful architecture fo
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea
InfinixTM CF-i/SP brings revolutionary flexibility to floor-mounted X-ray systems. The unique design enables operators to move the C-arm around the exam table as needed to obtain the optimal angle fo
Medicine Products: